Rhenman & Partners Asset Management AB Buys 41,500 Shares of Merus N.V. $MRUS
Rhenman & Partners Asset Management AB increased its stake in Merus N.V. by 55.7% in Q2, owning 116,000 shares worth $6.1 million. Other investors also increased their holdings. Analysts have mixed ratings on Merus, with a consensus 'Hold' rating and a $93.56 price target. Merus shares are trading at $96.02, with a market cap of $7.28 billion. The company develops antibody therapeutics, including Zenocutuzumab, in clinical trials for cancer treatment.
Rhenman & Partners Asset Management AB increased its stake in shares of Merus N.V. (NASDAQ:MRUS - Free Report) by 55.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 116,000 shares of the biotechnology company's stock after buying an additional 41,500 shares during the quarter. Rhenman & Partners Asset Management AB owned 0.15% of Merus worth $6,102,000 at the end of the most recent quarter.
Several other large investors have also bought and sold shares of the stock. Paradigm Biocapital Advisors LP raised its holdings in shares of Merus by 99.4% in the first quarter. Paradigm Biocapital Advisors LP now owns 3,369,699 shares of the biotechnology company's stock valued at $141,831,000 after purchasing an additional 1,679,777 shares during the last quarter. Wellington Management Group LLP increased its stake in Merus by 34.9% in the 1st quarter. Wellington Management Group LLP now owns 4,718,172 shares of the biotechnology company's stock valued at $198,588,000 after buying an additional 1,220,519 shares during the last quarter. Westfield Capital Management Co. LP lifted its position in shares of Merus by 36.0% during the 2nd quarter. Westfield Capital Management Co. LP now owns 2,042,388 shares of the biotechnology company's stock worth $107,430,000 after buying an additional 541,168 shares in the last quarter. Siren L.L.C. boosted its stake in shares of Merus by 33.0% in the 1st quarter. Siren L.L.C. now owns 1,043,467 shares of the biotechnology company's stock worth $43,920,000 after buying an additional 259,055 shares during the last quarter. Finally, Woodline Partners LP grew its holdings in shares of Merus by 17.8% in the first quarter. Woodline Partners LP now owns 1,400,171 shares of the biotechnology company's stock valued at $58,933,000 after acquiring an additional 211,653 shares in the last quarter. 96.14% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several research firms have weighed in on MRUS. William Blair cut Merus from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 29th. Lifesci Capital reaffirmed a "market perform" rating and issued a $97.00 price objective on shares of Merus in a research report on Tuesday, September 30th. Leerink Partners reissued a "market perform" rating and set a $97.00 target price (up from $95.00) on shares of Merus in a research report on Monday, October 6th. BMO Capital Markets restated a "market perform" rating and set a $97.00 price target on shares of Merus in a research note on Friday, October 31st. Finally, Wells Fargo & Company reiterated an "equal weight" rating and issued a $97.00 price objective (up previously from $95.00) on shares of Merus in a research note on Monday, September 29th. Three research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $93.56.
Read Our Latest Analysis on MRUS
Merus Trading Up 0.1%
Shares of MRUS opened at $96.02 on Wednesday. The stock has a 50-day moving average price of $90.75 and a 200-day moving average price of $70.00. The company has a market cap of $7.28 billion, a PE ratio of -18.12 and a beta of 1.26. Merus N.V. has a 12-month low of $33.19 and a 12-month high of $96.28.
Merus Profile
(Free Report)Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
Read More
- Five stocks we like better than Merus
- 5 Top Rated Dividend Stocks to Consider
- History Says These are 3 Stocks to Buy for December
- Short Selling - The Pros and Cons
- Warner Bros. Sale Rumors Heat Up: What Investors Need to Know
- Profitably Trade Stocks at 52-Week Highs
- From Science Project to Solvent: WeRide’s 761% Revenue Surge
Want to see what other hedge funds are holding MRUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merus N.V. (NASDAQ:MRUS - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Merus Right Now?
Before you consider Merus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.
While Merus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
